Ipamorelin Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for Ipamorelin:

• Mild transient hunger increase shortly after injection, though ipamorelin produces significantly less appetite stimulation than GHRP-6, which has strong orexigenic effects (PMID: 10580762)
• Headache, typically mild and most common during the first few weeks of use as the body adjusts to elevated GH levels
• Water retention and mild bloating, particularly in the hands and feet, consistent with GH-class effects from any secretagogue
• Tingling or numbness in the extremities (paresthesia), more common at higher doses or when combined with GHRH analogs
• Transient facial flushing shortly after injection, reported in community settings, typically resolving within minutes
• Potential decrease in insulin sensitivity with ongoing GH elevation: blood glucose monitoring is recommended for individuals at risk for diabetes (PMID: 28400207)
• Theoretical cancer risk: elevated IGF-1 has been epidemiologically associated with certain cancers, and no ipamorelin-specific data exists, though no clinical trial has demonstrated increased cancer incidence with GH secretagogues (PMID: 28400207)
• Joint pain or stiffness, less common than with direct HGH but reported at higher doses in community use

Severity and frequency

Limited clinical data is available for Ipamorelin. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: Ipamorelin is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology (1999) [PubMed]
• Growth hormone secretagogues: history, mechanism of action, and clinical development — JCSM Rapid Communications (2017) [PubMed]
• The effects of growth hormone-releasing peptide-6 and growth hormone-releasing hormone on the pulsatile growth hormone secretion in normal adult men — Journal of Clinical Endocrinology & Metabolism (1999) [PubMed]
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational Andrology and Urology (2020) [PubMed]
• The Safety and Efficacy of Growth Hormone Secretagogues — Sexual Medicine Reviews (2018) [PubMed]